204 related articles for article (PubMed ID: 36646323)
21. Outcomes Among High-Risk and Standard-Risk Multiple Myeloma Patients Treated With High-Dose Chemotherapy and Autologous Hematopoietic Stem-Cell Transplantation.
Kazmi SM; Nusrat M; Gunaydin H; Cornelison AM; Shah N; Kebriaei P; Nieto Y; Parmar S; Popat UR; Oran B; Shah JJ; Orlowski RZ; Champlin RE; Qazilbash MH; Bashir Q
Clin Lymphoma Myeloma Leuk; 2015 Nov; 15(11):687-93. PubMed ID: 26361647
[TBL] [Abstract][Full Text] [Related]
22. Impact of Autologous Transplantation in Patients with Multiple Myeloma with t(11;14): A Propensity-Score Matched Analysis.
Saini N; Ma J; Milton DR; Patel R; Varma A; Bashir Q; Delgado R; Mukherjee A; Rondon G; Popat UR; Hosing CM; Nieto Y; Kebriaei P; Alousi AM; Ahmed S; Tang G; Mehta R; Srour S; Khouri IF; Iyer S; Weber DM; Thomas SK; Lee HC; Manasanch EE; Patel KK; Orlowski RZ; Champlin RE; Qazilbash MH
Clin Cancer Res; 2019 Nov; 25(22):6781-6787. PubMed ID: 31481508
[TBL] [Abstract][Full Text] [Related]
23. Autologous stem cell transplantation in first remission is associated with better progression-free survival in multiple myeloma.
Aggarwal M; Agrawal N; Yadav N; Verma P; Ahmed R; Mehta P; Kapoor J; Bhurani D
Ann Hematol; 2018 Oct; 97(10):1869-1877. PubMed ID: 29781040
[TBL] [Abstract][Full Text] [Related]
24. Impact of pretransplant minimal residual disease in patients with multiple myeloma and a very good partial response or better receiving autologous hematopoietic stem cell transplantation.
Pasvolsky O; Pasyar S; Bassett RL; Khan HN; Tanner MR; Bashir Q; Srour S; Saini N; Lin P; Ramdial J; Nieto Y; Lee HC; Patel KK; Kebriaei P; Thomas SK; Weber DM; Orlowski RZ; Shpall EJ; Champlin RE; Qazilbash MH
Cancer; 2024 May; 130(9):1663-1672. PubMed ID: 38127583
[TBL] [Abstract][Full Text] [Related]
25. Prolonged survival with a longer duration of maintenance lenalidomide after autologous hematopoietic stem cell transplantation for multiple myeloma.
Mian I; Milton DR; Shah N; Nieto Y; Popat UR; Kebriaei P; Parmar S; Oran B; Shah JJ; Manasanch EE; Orlowski RZ; Shpall EJ; Champlin RE; Qazilbash MH; Bashir Q
Cancer; 2016 Dec; 122(24):3831-3837. PubMed ID: 27680710
[TBL] [Abstract][Full Text] [Related]
26. [Multiple myeloma: Maintenance therapy after autologous hematopoietic stem cell transplantation, depending on minimal residual disease].
Solovyev MV; Mendeleeva LP; Pokrovskaya OS; Nareyko MV; Firsova MV; Galtseva IV; Davydova YO; Kapranov NM; Kuzmina LA; Gemdzhian EG; Savchenko VG
Ter Arkh; 2017; 89(7):25-31. PubMed ID: 28766537
[TBL] [Abstract][Full Text] [Related]
27. [Treatment options and prognosis in newly diagnosed multiple myeloma patients].
Wang L; Tang W; Wang Y; Xu L; Zhao WL; Wu W; Chen YB; Shen ZX; Hu J
Zhonghua Xue Ye Xue Za Zhi; 2011 May; 32(5):308-12. PubMed ID: 21729598
[TBL] [Abstract][Full Text] [Related]
28. Achieving minimal residual disease-negative by multiparameter flow cytometry may ameliorate a poor prognosis in MM patients with high-risk cytogenetics: a retrospective single-center analysis.
Li H; Li F; Zhou X; Mei J; Song P; An Z; Zhao Q; Guo X; Wang X; Zhai Y
Ann Hematol; 2019 May; 98(5):1185-1195. PubMed ID: 30721336
[TBL] [Abstract][Full Text] [Related]
29. Allogeneic Hematopoietic Cell Transplantation in Multiple Myeloma: Impact of Disease Risk and Post Allograft Minimal Residual Disease on Survival.
Dhakal B; D'Souza A; Martens M; Kapke J; Harrington AM; Pasquini M; Saber W; Drobyski WR; Zhang MJ; Hamadani M; Hari PN
Clin Lymphoma Myeloma Leuk; 2016 Jul; 16(7):379-86. PubMed ID: 27160644
[TBL] [Abstract][Full Text] [Related]
30. Circulating Plasma Cells at the Time of Collection of Autologous PBSC for Transplant in Multiple Myeloma Patients is a Negative Prognostic Factor Even in the Age of Post-Transplant Maintenance Therapy.
Cowan AJ; Stevenson PA; Libby EN; Becker PS; Coffey DG; Green DJ; Hyun TS; Fromm JR; Gopal AK; Holmberg LA
Biol Blood Marrow Transplant; 2018 Jul; 24(7):1386-1391. PubMed ID: 29481870
[TBL] [Abstract][Full Text] [Related]
31. Characteristics and Outcomes of Patients With Multiple Myeloma Who Developed Therapy-Related Acute Myeloid Leukemia and Myelodysplastic Syndrome After Autologous Cell Transplantation.
Yalniz FF; Greenbaum U; Pasvolsky O; Milton DR; Kanagal-Shamanna R; Ramdial J; Srour S; Mehta R; Alousi A; Popat UR; Nieto Y; Kebriaei P; Al-Atrash G; Oran B; Hosing C; Ahmed S; Champlin RE; Shpall EJ; Qazilbash MH; Bashir Q
Transplant Cell Ther; 2024 Feb; 30(2):205.e1-205.e12. PubMed ID: 37437764
[TBL] [Abstract][Full Text] [Related]
32. Impact of Hepatitis B Core Antibody Seropositivity on the Outcome of Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma.
Varma A; Biritxinaga L; Saliba RM; Stich M; Jauch SF; Afrough A; Honhar M; Popat UR; Shafi MA; Shah N; Bashir Q; Dinh Y; Hosing C; Champlin RE; Qazilbash MH
Biol Blood Marrow Transplant; 2017 Apr; 23(4):581-587. PubMed ID: 28063964
[TBL] [Abstract][Full Text] [Related]
33. [Effects of Pre-Transplant CONUT and Post-Transplant MRD on Prognosis of Patients with Multiple Myeloma after Auto-HSCT].
Xiong YY; Zhou Q; Chen L; Yu W; Zhang HB; Chen JB
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Feb; 32(1):146-154. PubMed ID: 38387913
[TBL] [Abstract][Full Text] [Related]
34. Minimal residual disease status is the prognostic determinant following high-dose treatment for patients with multiple myeloma.
Nahi H; Afram G; Uttervall K; Lockmer S; Tätting L; Gahrton G; Kashif M; Alici E; Stromberg O; Klimkowska M; Lund J
Cancer Med; 2023 Nov; 12(22):20736-20744. PubMed ID: 37921243
[TBL] [Abstract][Full Text] [Related]
35. High-risk myeloma and minimal residual disease postautologous-HSCT predict worse outcomes.
Hu B; Thall P; Milton DR; Sasaki K; Bashir Q; Shah N; Patel K; Popat U; Hosing C; Nieto Y; Lin P; Delgado R; Jorgensen J; Manasanch E; Weber D; Thomas S; Orlowski RZ; Champlin R; Qazilbash MH
Leuk Lymphoma; 2019 Feb; 60(2):442-452. PubMed ID: 30032678
[TBL] [Abstract][Full Text] [Related]
36. Treatment patterns and clinical outcomes in high-risk newly diagnosed multiple myeloma patients carrying the 17p deletion: An observational multi-center retrospective study.
Cohen YC; Saranga A; Gatt ME; Lavi N; Ganzel C; Magen H; Avivi I; Tadmor T; Suriu C; Jarchowsky Dolberg O; Papushado A; Trestman S; Ram R
Am J Hematol; 2018 Jun; 93(6):810-815. PubMed ID: 29603773
[TBL] [Abstract][Full Text] [Related]
37. Outcomes of Maintenance Therapy with Bortezomib after Autologous Stem Cell Transplantation for Patients with Multiple Myeloma.
Sivaraj D; Green MM; Li Z; Sung AD; Sarantopoulos S; Kang Y; Long GD; Horwitz ME; Lopez RD; Sullivan KM; Rizzieri DA; Chao NJ; Gasparetto C
Biol Blood Marrow Transplant; 2017 Feb; 23(2):262-268. PubMed ID: 27856369
[TBL] [Abstract][Full Text] [Related]
38. [The prognostic value of dynamic minimal residual disease after autologous hematopoietic stem cell transplantation in patients with multiple myeloma in novel-agent era].
Yang GZ; Wang GR; Wang HJ; Zhang YR; Wu Y; Li YC; Liu AJ; Leng Y; Gao W; Chen WM
Zhonghua Yi Xue Za Zhi; 2022 Aug; 102(30):2345-2350. PubMed ID: 35970792
[No Abstract] [Full Text] [Related]
39. Impact of chromosomal abnormalities on the efficacy of lenalidomide plus dexamethasone treatment in patients with relapsed/refractory multiple myeloma.
Yoshida T; Ri M; Fujinami H; Oshima Y; Tachita T; Marumo Y; Sasaki H; Kinoshita S; Totani H; Narita T; Masaki A; Ito A; Kusumoto S; Ishida T; Komatsu H; Iida S
Int J Hematol; 2019 Aug; 110(2):228-236. PubMed ID: 31119611
[TBL] [Abstract][Full Text] [Related]
40. [Impact of minimal residual disease detection after treatment of multiple myeloma].
Szendrei T; Plander M; Szabó Z; Kereskai L; Kajtár B; Papp G; Iványi JL
Orv Hetil; 2019 Mar; 160(13):502-508. PubMed ID: 30907098
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]